Medical Properties Trust (NYSE:MPT) Rating Lowered to Neutral at BNP Paribas Exane

Medical Properties Trust (NYSE:MPT) was downgraded by analysts at BNP Paribas Exane from an “outperform” rating to a “neutral” rating in a research note issued to investors on Tuesday, Briefing.com reports. They currently have a $2.25 price target on the stock. BNP Paribas Exane‘s price target indicates a potential upside of 3.21% from the stock’s previous close.

MPT has been the subject of several other research reports. Wells Fargo & Company decreased their price target on Medical Properties Trust from $5.00 to $3.80 and set an “underweight” rating for the company in a report on Tuesday, September 1st. Weiss Ratings lowered Medical Properties Trust from a “sell (d+)” rating to a “sell (d)” rating in a research report on Tuesday, August 18th. Finally, Royal Bank Of Canada cut Medical Properties Trust from a “sector perform” rating to an “underperform” rating and dropped their price objective for the company from $4.50 to $2.00 in a research note on Friday. One investment analyst has rated the stock with a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, Medical Properties Trust has an average rating of “Strong Sell” and an average target price of $2.68.

Medical Properties Trust Price Performance

MPT stock opened at $2.18 on Tuesday. The company has a debt-to-equity ratio of 2.16, a quick ratio of 3.12 and a current ratio of 3.12. The business has a 50-day simple moving average of $3.38 and a two-hundred day simple moving average of $4.34. The company has a market capitalization of $1.30 billion, a P/E ratio of 5.32 and a beta of 1.45. Medical Properties Trust has a 52-week low of $2.03 and a 52-week high of $6.47.

Medical Properties Trust (NYSE:MPT) last issued its quarterly earnings data on Thursday, October 29th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.13 by ($0.02). Medical Properties Trust had a negative return on equity of 0.66% and a negative net margin of 2.96%. The company had revenue of $250.14 million during the quarter. Medical Properties Trust’s quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts expect that Medical Properties Trust will post 0.53 EPS for the current fiscal year.

Institutional Trading of Medical Properties Trust

A number of institutional investors and hedge funds have recently modified their holdings of MPT. Amundi boosted its position in Medical Properties Trust by 1.6% during the second quarter. Amundi now owns 388,683 shares of the company’s stock worth $1,796,000 after purchasing an additional 6,252 shares during the period. Continuum Advisory LLC purchased a new position in shares of Medical Properties Trust in the second quarter worth about $31,000. CoreCap Advisors LLC purchased a new position in shares of Medical Properties Trust in the third quarter worth about $27,000. Nykredit A S purchased a new position in shares of Medical Properties Trust in the second quarter worth about $41,000. Finally, NFSG Corp bought a new stake in shares of Medical Properties Trust in the third quarter valued at approximately $34,000. 71.79% of the stock is owned by hedge funds and other institutional investors.

Medical Properties Trust Company Profile

Medical Properties Trust, Inc is a healthcare-focused real estate investment trust (REIT) that owns and invests in healthcare facilities. Its portfolio has historically included hospitals, inpatient rehabilitation facilities, long-term acute-care hospitals, behavioral health facilities and other properties used by healthcare providers.

Founded in 2003 and headquartered in Birmingham, Alabama, the company primarily generates income by leasing properties to healthcare operators under long-term agreements.